Zoetis Inc. $ZTS Shares Sold by Keybank National Association OH

Keybank National Association OH lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 34.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 106,387 shares of the company’s stock after selling 55,289 shares during the period. Keybank National Association OH’s holdings in Zoetis were worth $12,576,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Heritage Investors Management Corp grew its stake in shares of Zoetis by 2.2% during the first quarter. Heritage Investors Management Corp now owns 209,297 shares of the company’s stock worth $24,741,000 after purchasing an additional 4,496 shares in the last quarter. Physician Wealth Advisors Inc. raised its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares in the last quarter. KPP Advisory Services LLC lifted its holdings in Zoetis by 9.1% during the 1st quarter. KPP Advisory Services LLC now owns 8,257 shares of the company’s stock worth $976,000 after buying an additional 690 shares during the last quarter. Smithbridge Asset Management Inc. DE acquired a new position in shares of Zoetis during the 1st quarter worth about $1,544,000. Finally, Vision Capital Management Inc. increased its holdings in shares of Zoetis by 3.2% in the 1st quarter. Vision Capital Management Inc. now owns 34,861 shares of the company’s stock valued at $4,121,000 after acquiring an additional 1,094 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.1%

ZTS opened at $74.73 on Friday. The business has a 50 day moving average price of $84.04 and a two-hundred day moving average price of $109.40. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market cap of $31.33 billion, a PE ratio of 12.39, a P/E/G ratio of 1.17 and a beta of 0.75. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $161.77.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. TD Cowen reduced their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Finally, Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $126.92.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.